Biocartis Group NV: DISCLOSURE OF OUTSTANDING VOTING SECURITIES

NEXT STORY
Curetis to Publish its Full-Year 2018 Financial Results on April 11, 2019
PREV STORY
Profound Medical Announces Positive Topline Results from TACT Pivotal Clinical Trial of TULSA-PRO® in Patients with Prostate Cancer
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Global Syndromic Multiplex Diagnostic Market to 2023 – POC Testing & Molecular Diagnostics are Merging with Spectacular Success, Possibly Displacing Most Frontline Test Protocols

author_avatar
NASDAQ Market News

Trulicity® (dulaglutide) is now indicated as an adjunct to diet, exercise, and standard of care therapy to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease

author_avatar
NASDAQ Market News

Crohn’s and Colitis Canada Celebrates the 10th Anniversary of the AbbVie IBD Scholarship Program

author_avatar
NASDAQ Market News